• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email
    SC 13G/A 1 sudb20230113_sc13ga.htm SCHEDULE 13G/A sudb20230113_sc13ga.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    Mannatech, Incorporated

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    563771203

    (CUSIP Number)

     

    Dayton Judd

    Sudbury Capital Fund, LP

    136 Oak Trail

    Coppell, TX 75019

    972-304-5000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [   ] Rule 13d-1(b)

    [X] Rule 13d-1(c)

    [   ] Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     



     

     

     

    CUSIP NO. 563771203

    13G

    Page 2 of 10

     

    (1) 

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Dayton Judd

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  

    (b)  

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    USA

    NUMBER

    OF SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    (5)

    Sole Voting Power  

     

    2,500

    (6)

    Shared Voting Power

     

    138,639 (1)

    (7)

    Sole Dispositive Power  

     

    2,500

    (8)

    Shared Dispositive Power  

     

    138,639 (1)

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    141,139

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    7.6% (2)

    (12)

    Type of Reporting Person (See Instructions)

     

    Individual (IN)

     

    (1)

    Includes (i) 393 shares of Common Stock held indirectly by Mr. Judd through his spouse; and (ii) 138,246 shares of Common Stock held by Sudbury Capital Fund, LP. The general partner of Sudbury Capital Fund, LP is Sudbury Capital GP, LP, of which Sudbury Holdings, LLC is the general partner. The sole member of Sudbury Holdings, LLC is Mr. Judd. Mr. Judd may therefore be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP pursuant to Section 13d-3 of the Act.

     

    (2)

    Based on 1,858,467 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2022.

     

     

     

     

    CUSIP NO. 563771203

    13G

    Page 3 of 10

     

    (1) 

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Sudbury Capital Fund, LP   

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  

    (b)  

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    Delaware

    NUMBER

    OF SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    (5)

    Sole Voting Power  

     

    0

    (6)

    Shared Voting Power  

     

    138,246

    (7)

    Sole Dispositive Power  

     

    0

    (8)

    Shared Dispositive Power  

     

    138,246

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    138,246

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    7.4% (1)

    (12)

    Type of Reporting Person (See Instructions)

     

    Partnership (PN)

     

    (1)

    Based on 1,858,467 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2022.

     

     

     

     

    CUSIP NO. 563771203

    13G

    Page 4 of 10

     

    (1) 

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Sudbury Holdings, LLC

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  

    (b)  

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    Texas

    NUMBER

    OF SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    (5)

    Sole Voting Power  

     

    0

    (6)

    Shared Voting Power  

     

    138,246 (1)

    (7)

    Sole Dispositive Power  

     

    0

    (8)

    Shared Dispositive Power

     

    138,246 (1)

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    138,246

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    7.4% (2)

    (12)

    Type of Reporting Person (See Instructions)

     

    Parent Holding Company/Control Person (HC)

     

    (1)

    Includes 138,246 shares of Common Stock held by Sudbury Capital Fund, LP. Because Sudbury Holdings, LLC is the indirect general partner of Sudbury Capital Fund, LP, Sudbury Holdings, LLC may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (2)

    Based on 1,858,467 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2022.

     

     

     

     

    CUSIP NO. 563771203

    13G

    Page 5 of 10

     

    (1) 

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Sudbury Capital Fund GP, LP   

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  

    (b)  

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    Texas

    NUMBER

    OF SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    (5)

    Sole Voting Power  

     

    0

    (6)

    Shared Voting Power  

     

    138,246 (1)

    (7)

    Sole Dispositive Power  

     

    0

    (8)

    Shared Dispositive Power  

     

    138,246 (1)

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    138,246

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    7.4% (2 )

    (12)

    Type of Reporting Person (See Instructions)

     

    Partnership (PN)

     

    (1)

    Includes 138,246 shares of Common Stock held by Sudbury Capital Fund, LP. Because Sudbury Capital GP, LP is the general partner of Sudbury Capital Fund, LP, Sudbury Capital GP, LP may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (2)

    Based on 1,858,467 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2022.

     

     

     

     

    CUSIP NO. 563771203

    13G

    Page 6 of 10

     

    (1) 

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

    Sudbury Capital Management, LLC

    (2)

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  

    (b)  

    (3)

    SEC Use Only

     

    (4)

    Citizenship or Place of Organization

     

    Texas

    NUMBER

    OF SHARES

    BENEFICIALLY

    OWNED

    BY EACH

    REPORTING

    PERSON

    WITH

    (5)

    Sole Voting Power  

     

    0

    (6)

    Shared Voting Power  

     

    138,246 (1)

    (7)

    Sole Dispositive Power  

     

    0

    (8)

    Shared Dispositive Power  

     

    138,246 (1)

    (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    138,246

    (10)

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares   [   ]

     

    (See Instructions)

    (11)

    Percent of Class Represented by Amount in Row (9)

     

    7.4% (2)

    (12)

    Type of Reporting Person (See Instructions)

     

    Investment Advisor (IA)

     

    (1)

    Includes 138,246 shares of Common Stock held by Sudbury Capital Fund, LP. Because Sudbury Capital Management, LLC is the Investment Adviser of Sudbury Capital Fund, LP, Sudbury Capital Management, LLC, may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (2)

    Based on 1,858,467 shares of Common Stock outstanding as of October 31, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed November 8, 2022.

     

     

     

     

     

    Item 1.

     

    (a)

     

    Name of Issuer

     

       

    The name of the issuer is Mannatech, Incorporated (herein referred to as “Issuer”).

     

     

    (b)

     

    Address of Issuers Principal Executive Offices

     

       

    The principal executive offices of the Issuer are located at 1410 Lakeside Parkway, Suite 200, Flower Mound, Texas 75028.

     

    Item 2.

     

    (a)

     

    Name of Person Filing

     

       

    Pursuant to Regulation 13D-G of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the “Act”), the undersigned hereby files this Schedule 13G Statement on behalf of Sudbury Capital Fund, LP, a Delaware limited partnership; Sudbury Holdings, LLC, a Texas limited liability company; Sudbury Capital Management, LLC, a Texas limited liability company; Sudbury Capital GP, LP, a Texas limited partnership; and Dayton Judd, the Reporting Persons. The Reporting Persons are filing this statement jointly. Neither the fact of this filing nor anything contained herein shall be deemed to be an admission by any of the Reporting Persons that they constitute a group.

     

     

    (b)

     

    Address of the Principal Office or, if none, residence

     

       

    The address of the business office of Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital Management, LLC, Sudbury Capital GP, LP and Dayton Judd is 136 Oak Trail, Coppell, TX 75019.

     

     

    (c)

     

    Citizenship

     

       

    Mr. Judd is a citizen of the United States of America.

     

     

    (d)

     

    Title of Class of Securities

     

       

    The Schedule 13G statement relates to common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

     

    (e)

     

    CUSIP Number

     

       

    The CUSIP number for the Common Stock is 563771203.

         

    Item 3.

     

     

    Filing pursuant to 240.13d-1(c) 

     

       

    This Schedule 13G statement is not being filed pursuant to Rule 13d-1(b), Rule 13d-1(d), Rule 13d-2(b) or Rule 13d-2(d). 

     

     

     

     

     

    Item 4. Ownership

     

    Dayton Judd:

     

    Mr. Judd is the sole member of Sudbury Holdings, LLC. Sudbury Holdings, LLC is the general partner of Sudbury Capital GP, LP, which is the general partner of Sudbury Capital Fund, LP. Sudbury Capital Fund, LP is the beneficial owner of 138,246 shares of Common Stock reported on this Amendment No. 4 to Schedule 13G. Mr. Judd may therefore be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP pursuant to Section 13d-3 of the Act. In addition, Mr. Judd and his spouse hold 2,893 shares of Common Stock directly through individual retirement accounts.

     

    (a)

    Amount beneficially owned:

    141,139

    (b)

    Percent of class:

    7.6%

    (c)

    Number of shares to which the person has:

     
     

    (i)

    Sole power to vote or to direct the votes:

    2,500

     

    (ii)

    Shared power to vote or to direct the vote:

    138,639

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    2,500

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    138,639

     

    Sudbury Capital Fund, LP:

     

    (a)

    Amount beneficially owned:

    138,246

    (b)

    Percent of class:

    7.4%

    (c)

    Number of shares to which the person has:

     
     

    (i)

    Sole power to vote or to direct the votes:

    0

     

    (ii)

    Shared power to vote or to direct the vote:

    138,246

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    138,246

     

    Sudbury Holdings, LLC:

     

    Because Sudbury Holdings, LLC is the indirect general partner of Sudbury Capital Fund, LP, Sudbury Holdings, LLC may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (a)

    Amount beneficially owned:

    138,246

    (b)

    Percent of class:

    7.4%

    (c)

    Number of shares to which the person has:

     
     

    (i)

    Sole power to vote or to direct the votes:

    0

     

    (ii)

    Shared power to vote or to direct the vote:

    138,246

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    138,246

     

    Sudbury Capital GP, LP:

     

    Because Sudbury Capital GP, LP is the general partner of Sudbury Capital Fund, LP, Sudbury Capital GP, LP may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (a)

    Amount beneficially owned:

    138,246

    (b)

    Percent of class:

    7.4%

    (c)

    Number of shares to which the person has:

     
     

    (i)

    Sole power to vote or to direct the votes:

    0

     

    (ii)

    Shared power to vote or to direct the vote:

    138,246

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    138,246

     

     

     

     

    Sudbury Capital Management, LLC:

     

    Because Sudbury Capital Management, LLC is the Investment Adviser of Sudbury Capital Fund, LP, Sudbury Capital Management, LLC, may, pursuant to Section 13d-3 of the Act, be deemed to be the beneficial owner of the shares of Common Stock held by Sudbury Capital Fund, LP.

     

    (a)

    Amount beneficially owned:

    138,246

    (b)

    Percent of class:

    7.4%

    (c)

    Number of shares to which the person has:

     
     

    (i)

    Sole power to vote or to direct the votes:

    0

     

    (ii)

    Shared power to vote or to direct the vote:

    138,246

     

    (iii)

    Sole power to dispose or to direct the disposition of:

    0

     

    (iv)

    Shared power to dispose or to direct the disposition of:

    138,246

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not Applicable

     

    Item 6. Ownership of More than Five Percent on Behalf of another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

    Item 10. Certification

     

    The following certification shall be included if the statement is filed pursuant to 240.13d-1(c):

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:   January 13, 2023

    /s/ Dayton Judd

    Name: Dayton Judd

     

     

    Date:   January 13, 2023

     

    Sudbury Capital Fund, LP

     

     

    By:

    /s/ Dayton Judd

       

    Name: Dayton Judd

       

    Title: Member of the General Partner of the General Partner of Sudbury Capital Fund, LP

     

     

    Date:   January 13, 2023

     

    Sudbury Holdings, LLC

     

     

    By:

    /s/ Dayton Judd

       

    Name: Dayton Judd

       

    Title: Sole Member

     

     

    Date:   January 13, 2023

     

    Sudbury Capital GP, LP

     

     

    By:

    /s/ Dayton Judd

       

    Name: Dayton Judd

       

    Title: Member of the General Partner of Sudbury Capital GP, LP

     

     

    Date:   January 13, 2023

     

    Sudbury Capital Management, LLC

     

     

    By:

    /s/ Dayton Judd

       

    Name: Dayton Judd

       

    Title: Managing Member

     

     

     

     

     
    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more

    $MTEX
    SEC Filings

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care